The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma
- 1 September 2007
- journal article
- Published by Wiley in Histopathology
- Vol. 51 (3), 322-335
- https://doi.org/10.1111/j.1365-2559.2007.02757.x
Abstract
To clarify MUC1 patterns in invasive ductal breast carcinoma and to relate them to clinicopathological parameters, coexpression of other biological markers and prognosis. Samples from 243 consecutive patients with primary ductal carcinoma were incorporated into tissue microarrays (TMAs). Slides were stained for MUC1, oestrogen receptor (ER), progesterone receptor (PR), Her2/neu, p53 and cyclin D1. Apical membrane MUC1 expression was associated with smaller tumours (P = 0.001), lower tumour grades (P < 0.001), PR positivity (P = 0.003) and increased overall survival (OS; P = 0.030). Diffuse cytoplasmic MUC1 expression was associated with cyclin D1 positivity (P = 0.009) and increased relapse-free survival (RFS; P = 0.034). Negativity for MUC1 was associated with ER negativity (P = 0.004), PR negativity (P = 0.001) and cyclin D1 negativity (P = 0.009). In stepwise multivariate analysis MUC1 negativity was an independent predictor of both RFS [hazard ratio (HR) 3.5, 95% confidence interval (CI) 1.5, 8.5; P = 0.005] and OS (HR 14.7, 95% CI 4.9, 44.1; P < 0.001). The expression pattern of MUC1 in invasive ductal breast carcinoma is related to tumour characteristics and clinical outcome. In addition, negative MUC1 expression is an independent risk factor for poor RFS and OS, besides 'classical' prognostic indicators.Keywords
This publication has 34 references indexed in Scilit:
- The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breastHistopathology, 2007
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinomaCancer, 2004
- Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor markerInternational Journal of Gynecologic Cancer, 2002
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.Molecular Biology of the Cell, 1996
- The epithelial mucin, MUC1, of milk, mammary gland and other tissuesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995
- Delayed Mammary Tumor Progression in Muc-1 Null MicePublished by Elsevier BV ,1995
- Critical evaluation of monoclonal antibody staining in breast carcinoma.Journal of Clinical Pathology, 1989
- Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patientsBreast Cancer Research and Treatment, 1985